

Serial No.: 09/742,148

Filed: December 19, 2000

amendment contains no new matter. Applicant submits that this amendment, the accompanying computer readable sequence listing, and the paper copy thereof serve to place this application in a condition of adherence to the rules 37 C.F.R. § 1.821-1.825.

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP



Todd A. Lorenz
Reg. No. 39,754

Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989

Serial No.: 09/742,148
Filed: December 19, 2000



RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Paragraph beginning at page 3, line 16, has been amended as follows:

-- Methods and compositions are provided for modulating lymphocytic activity, particularly CTL and NK cell activity, *in vitro* and *in vivo*. The compositions comprise oligopeptides of at least 6 amino acids comprising the tripeptide or triad (SEQ ID NO: 1) TYR-TYR-TRP (YYW), preferably the tetrapeptide (SEQ ID NO: 2) ARG-~~TRY~~-TYR-TYR-TRP (RYYW).--

Paragraph beginning at page 4, line 17, has been amended as follows:

-- For the most part, the oligopeptides will have at least 6, usually at least 8, amino acids, include the triad and come within the following formula: aa⁷⁰ aa⁷¹ Q aa⁷³ aa⁷⁴ R aa⁷⁶ aa⁷⁷ L aa⁷⁹ aa⁸⁰ aa⁸¹ aa⁸² aa⁸³ Y Y W aa⁸⁷ aa⁸⁸ aa⁸⁹ aa⁹⁰ aa⁹¹ (SEQ ID NO: 57).--

On page 64, immediately preceding the claims, the enclosed text entitled "SEQUENCE LISTING" was inserted into the text.